Saad F, et al. - Researchers determined how health-related quality of life (HRQOL) was affected by the use of apalutamide vs placebo added to androgen deprivation therapy among men with non-metastatic castration-resistant prostate cancer who were at high risk for development of metastases from the SPARTAN trial, which is a multicenter, international, randomized, phase 3 trial. Findings revealed that HRQOL was preserved after beginning apalutamide treatment in asymptomatic men with high-risk non-metastatic castration-resistant prostate cancer. Along with findings from SPARTAN, longer metastasis-free survival and longer time to symptomatic progression were seen in patients treated with apalutamide vs placebo, with preserved HRQOL.